PFBT
VRDN icon

Parkside Financial Bank & Trust’s Viridian Therapeutics VRDN Stock Holding History

Parkside Financial Bank & Trust’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29K Hold
70
– – ﹤0.01% 2330
2026
Q1 		$1.37K Hold
70
– – ﹤0.01% 2240
2025
Q4 		$2.18K Hold
70
– – ﹤0.01% 2069
2025
Q3 		$1.51K Hold
70
– – ﹤0.01% 2121
2025
Q2 		$978 Buy
+70
New +$950 ﹤0.01% 2279

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Parkside Financial Bank & Trust's VRDN Position: Q2 2026 in Review

Parkside Financial Bank & Trust held its Viridian Therapeutics (VRDN) position steady in Q2 2026 at 70 shares worth $1.29K. The position accounts for ﹤0.01% of the portfolio, ranked #2330.

Parkside Financial Bank & Trust first reported a position in VRDN in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.18K in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Parkside Financial Bank & Trust held 70 shares of Viridian Therapeutics worth $1.29K as of Q2 2026.
  • Parkside Financial Bank & Trust left its Viridian Therapeutics share count unchanged in Q2 2026.
  • Viridian Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #2330 holding.
  • Parkside Financial Bank & Trust first reported a position in Viridian Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Parkside Financial Bank & Trust's Viridian Therapeutics position peaked at $2.18K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.